These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27741259)

  • 1. Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia Prior to 35 Weeks' Gestation: A Budget Impact Analysis.
    Duckworth S; Chappell LC; Seed PT; Mackillop L; Shennan AH; Hunter R
    PLoS One; 2016; 11(10):e0164276. PubMed ID: 27741259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis.
    Duhig KE; Seed PT; Myers JE; Bahl R; Bambridge G; Barnfield S; Ficquet J; Girling JC; Khalil A; Shennan AH; Chappell LC; Hunter RM
    BJOG; 2019 Oct; 126(11):1390-1398. PubMed ID: 31240854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
    Duhig KE; Myers J; Seed PT; Sparkes J; Lowe J; Hunter RM; Shennan AH; Chappell LC;
    Lancet; 2019 May; 393(10183):1807-1818. PubMed ID: 30948284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK.
    Vatish M; Strunz-McKendry T; Hund M; Allegranza D; Wolf C; Smare C
    Ultrasound Obstet Gynecol; 2016 Dec; 48(6):765-771. PubMed ID: 27300726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study.
    McCarthy FP; Gill C; Seed PT; Bramham K; Chappell LC; Shennan AH
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):62-67. PubMed ID: 29575304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
    Frampton GK; Jones J; Rose M; Payne L
    Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placental Growth Factor (PlGF)- Based Biomarker Testing to Help Diagnose Pre-eclampsia in People With Suspected Pre-eclampsia: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2023; 23(3):1-146. PubMed ID: 37284279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
    Litwinska M; Syngelaki A; Wright A; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2018 Sep; 52(3):365-372. PubMed ID: 29943498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting.
    Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S
    Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany.
    Schlembach D; Hund M; Schroer A; Wolf C
    BMC Health Serv Res; 2018 Aug; 18(1):603. PubMed ID: 30081904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2).
    Hurrell A; Sparkes J; Duhig K; Seed PT; Myers J; Battersby C; Clark K; Green M; Hunter RM; Shennan AH; Chappell LC; Webster L
    Trials; 2022 Sep; 23(1):722. PubMed ID: 36056408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental growth factor in assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a stepped wedge cluster randomised control trial (PARROT Ireland).
    Hayes-Ryan D; Khashan AS; Hemming K; Easter C; Devane D; Murphy DJ; Hunter A; Cotter A; McAuliffe FM; Morrison JJ; Breathnach FM; Dempsey E; Kenny LC; O'Donoghue K;
    BMJ; 2021 Aug; 374():n1857. PubMed ID: 34389547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
    Hurrell A; Webster L; Sparkes J; Battersby C; Brockbank A; Clark K; Duhig KE; Gill C; Green M; Hunter RM; Seed PT; Vowles Z; Myers J; Shennan AH; Chappell LC;
    Lancet; 2024 Feb; 403(10427):619-631. PubMed ID: 38342128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
    Wright D; Dragan I; Syngelaki A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):194-200. PubMed ID: 27671544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical evaluation of placental growth factor in routine practice in high-risk women presenting with suspected pre-eclampsia and/or fetal growth restriction.
    Ormesher L; Johnstone ED; Shawkat E; Dempsey A; Chmiel C; Ingram E; Higgins LE; Myers JE
    Pregnancy Hypertens; 2018 Oct; 14():234-239. PubMed ID: 29559205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals.
    Figueira SF; Wolf C; D'Innocenzo M; de Carvalho JPV; Barbosa MG; Zlotnik E; Cordioli E
    Pregnancy Hypertens; 2018 Jul; 13():30-36. PubMed ID: 30177068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 35-37 weeks' gestation.
    Panaitescu AM; Wright D; Militello A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):383-387. PubMed ID: 28133834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.